Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT03390738Phase 2Withdrawn
- Sponsor
- The University of Hong Kong
- Start
- Jun 2018
- Primary completion
- May 2019
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of nivolumab in nasopharyngeal carcinoma (NPC), sponsored by The University of Hong Kong. Planned start Jun 2018; status: withdrawn.
02
Drugs
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03390738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03390738.